ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...
California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...
We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...
The New Republic on MSN1dOpinion
RFK Jr.’s Most Surprising Ally is the LA Times Owner. Here’s Why.One of Robert F. Kennedy Jr.’s most devoted cheerleaders, Dr. Patrick Soon-Shiong, the billionaire owner of the Los Angeles ...
The partnership involves the conduct of a confirmatory randomized Phase 3 clinical trial combining BeiGene’s tislelizumab and ImmunityBio’s Anktiva, which aims to confirm the efficacy and ...
After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...
January 27, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun assessing the marketing ...
The New Republic on MSN7hOpinion
Elon Musk’s Ego Sure to Get Massive Blow from Stunning Poll ResultsOne of Robert F. Kennedy Jr.’s most devoted cheerleaders, Dr. Patrick Soon-Shiong, the billionaire owner of the Los Angeles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback